EMAIL THIS PAGE TO A FRIEND

BioMed research international

Alpha-mangostin attenuation of hyperglycemia-induced ocular hypoperfusion and blood retinal barrier leakage in the early stage of type 2 diabetes rats.


PMID 25950001

Abstract

The present study examined effects of alpha-mangostin (α-MG) supplementation on the retinal microvasculature, including ocular blood flow (OBF) and blood-retinal barrier (BRB) permeability in a type 2 diabetic animal model. Male Sprague-Dawley rats were divided into four groups: normal control and diabetes with or without α-MG supplementation. Alpha-mangostin (200 mg/Kg/day) was administered by gavage feeding for 8 weeks. The effects of α-MG on biochemical and physiological parameters including mean arterial pressure (MAP), OBF, and BRB leakage were investigated. Additionally, levels of retinal malondialdehyde (MDA), advance glycation end products (AGEs), receptor of advance glycation end products (RAGE), tumour necrosis factor alpha (TNF-α), and vascular endothelial growth factor (VEGF) were evaluated. The elevated blood glucose, HbA1c, cholesterol, triglyceride, serum insulin, and HOMA-IR were observed in DM2 rats. Moreover, DM2 rats had significantly decreased OBF but statistically increased MAP and leakage of the BRB. The α-MG-treated DM2 rats showed significantly lower levels of retinal MDA, AGEs, RAGE, TNF-α, and VEGF than the untreated group. Interestingly, α-MG supplementation significantly increased OBF while it decreased MAP and leakage of BRB. In conclusion, α-MG supplementation could restore OBF and improve the BRB integrity, indicating its properties closely associated with antihyperglycemic, antioxidant, anti-inflammatory, and antiglycation activities.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

T5500
2-Thiobarbituric acid, ≥98%
C4H4N2O2S
31640
4,4′-Diaminodiphenylmethane, analytical standard
C13H14N2
32950
4,4′-Diaminodiphenylmethane, ≥97.0% (GC)
C13H14N2
S5770
Citrate Concentrated Solution, BioReagent, suitable for coagulation assays, 4 % (w/v)
C6H5Na3O7
83273
Citrate Concentrated Solution, BioUltra, for molecular biology, 1 M in H2O
C6H5Na3O7
C3674
Citric acid trisodium salt, anhydrous, ≥98% (GC)
C6H5Na3O7
F9037
Formamide, ≥99.5% (GC), BioReagent, for molecular biology
CH3NO
221198
Formamide, ACS reagent, ≥99.5%
CH3NO
47671
Formamide, BioUltra, for molecular biology, ≥99.5% (T)
CH3NO
613339
Formamide solution, NMR reference standard, 90% in DMSO-d6 (99.9 atom % D), NMR tube size 3 mm × 8 in.
CH3NO
551384
Formamide solution, NMR reference standard, 90% in DMSO-d6 (99.9 atom % D), NMR tube size 5 mm × 8 in.
CH3NO
612707
Formamide solution, NMR reference standard, 45% in DMSO-d6 (99.9 atom % D), NMR tube size 3 mm × 8 in.
CH3NO
611891
Formamide solution, NMR reference standard, 45% in DMSO-d6 (99.9 atom % D), NMR tube size 5 mm × 8 in.
CH3NO
733784
Formamide solution, NMR reference standard, 90% in DMSO-d6 (99.9 atom % D), NMR tube size 10 mm × 8 in.
CH3NO
736201
Formamide solution, NMR reference standard, 90% in DMSO-d6 (99.9 atom % D), NMR tube size 5 mm × 8 in.
CH3NO
PHR1416
Sodium Citrate, Pharmaceutical Secondary Standard; Certified Reference Material
C6H5Na3O7 · 2H2O
S0130
Streptozocin, ≥75% α-anomer basis, ≥98% (HPLC), powder
C8H15N3O7